Too many middlemen disconnects you from patients.

See How Close
Lost in Transition Telephones
Lost in Transition

Treating rare disease shouldn’t be like a bad game of telephone, with each step generating chaos and confusion. Patient adherence suffers, quality of care diminishes, manufacturers miss out on vital feedback and cost goes up. But imagine if you could cut past all that. We did.

Learn More


Learn what's happening in the world of Dohmen and our clients
July 20, 2017

Dohmen leads keynote panel at Patient Support Services and HUB Design Summit, July 24-25

Patients are empowered like never before. This summit brings together orphan drug manufacturers, BPOs, doctors and researchers to build better awareness and understanding of patients’ needs.
learn more
June 21, 2017

Dohmen proudly sponsors the 26th Alpha-1 National Education Conference, June 23-25

The Dohmen Life Science Services (DLSS) team will join hundreds of rare disease experts, patients and caregivers at the 26th Alpha-1 National Education Conference in Chicago, IL.
learn more
June 16, 2017

Dohmen welcomes Lynda Parker, Chief Business Development Officer, Direct-to-Patient Services, DLSS

With more than 30 years of experience, Linda has successfully led product commercialization and helped orphan drug manufacturers overcome the challenges faced in serving and providing ongoing support to the rare disease community.
learn more
June 08, 2017

Dohmen celebrates with NORD Rare Impact Award Winners

The Dohmen team recently joined more than 400 people at the National Organization for Rare Disorders (NORD) 2017 Impact Awards ceremony in Washington, D.C. The inspiring evening celebrated individuals and organizations who are making extraordinary contributions to the rare disease community.
learn more
May 17, 2017

Dohmen welcomes Todd Sparlin, Vice President, Client Finance, DLSS

Dohmen has appointed Todd Sparlin as its new Vice President of Client Finance for Dohmen Life Science Services. With more than 20 years of experience in the finance and healthcare industries, he focuses on implementing financial strategies to increase clients’ profitability, improve cash flow and optimize investments.
learn more
May 10, 2017

Dohmen's high-touch patient support model featured in PharmaVOICE

A recent issue of PharmaVOICE highlights how the integrated model for rare disease patient support helps improve therapy adherence and build better patient relationships.
learn more
May 08, 2017

Dohmen announces new Vice President, Contracting and Payer Access, DLSS

Dohmen has appointed Brian Davis as its new Vice President of Contracting and Payer Access for orphan drug manufacturers for Dohmen Life Science Services. With 15 years of experience in managed care contracting, he has held roles leading both contracting and compliance departments. He’s also a pharmacist and has an extensive background in public policy and professional regulation.
learn more
March 27, 2017

Dohmen releases new white paper on improved outsourcing model for orphan drug manufacturers

The $114 billion orphan drug industry is traditionally served by a multi-channel model of disparate service providers. Each claims expertise in a specific niche of services, yet therapy adherence for rare disease patients is just over 58 percent. The Dohmen Life Science Services white paper explores an integrated outsourcing model that’s driving better adherence, supporting healthier outcomes and helping orphan drug manufacturers continuously improve their patient program with lower cost and less risk. Industry experts and patient advocates weigh in on why business process outsourcing must evolve.
learn more